Advertisement
UK markets closed
  • FTSE 100

    8,433.76
    +52.41 (+0.63%)
     
  • FTSE 250

    20,645.38
    +114.08 (+0.56%)
     
  • AIM

    789.87
    +6.17 (+0.79%)
     
  • GBP/EUR

    1.1631
    +0.0020 (+0.17%)
     
  • GBP/USD

    1.2536
    +0.0012 (+0.10%)
     
  • Bitcoin GBP

    48,556.48
    -1,136.83 (-2.29%)
     
  • CMC Crypto 200

    1,260.73
    -97.28 (-7.16%)
     
  • S&P 500

    5,216.76
    +2.68 (+0.05%)
     
  • DOW

    39,491.12
    +103.36 (+0.26%)
     
  • CRUDE OIL

    78.51
    -0.75 (-0.95%)
     
  • GOLD FUTURES

    2,370.20
    +29.90 (+1.28%)
     
  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     
  • HANG SENG

    18,963.68
    +425.87 (+2.30%)
     
  • DAX

    18,772.85
    +86.25 (+0.46%)
     
  • CAC 40

    8,219.14
    +31.49 (+0.38%)
     

Analysts’ Views on Sanofi, Pre-1Q18 Earnings Release

Analysts’ Views on Sanofi, Pre-1Q18 Earnings Release

In 1Q18, analysts expect Sanofi’s (SNY) revenue to fall ~6.6% YoY (year-over-year) to 8.1 billion euros from 8.7 billion euros, and its earnings per share to fall to 1.13 euros from 1.42 euros. Sanofi’s stock price has fallen ~9.4% over the last 12 months and ~7.1% year-to-date. Analysts’ price target of $47.67 suggests the stock could return ~19.2% over the next 12 months based on its price of $39.95 on April 23.